Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma: a nationwide discrete choice experiment
Adjuvant treatment decisions in stage IIB/C melanoma require careful weighing of benefits and risks. Our aim was to investigate how dermato-oncologists in Germany prioritize efficacy, toxicity, and application mode of modern adjuvants in these stages. In a nationwide discrete choice experiment physi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
Sep 25, 2025
|
| In: |
Acta dermato-venereologica
Year: 2025, Jahrgang: 105, Pages: 1-8 |
| ISSN: | 1651-2057 |
| DOI: | 10.2340/actadv.v105.44135 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.2340/actadv.v105.44135 Verlag, kostenfrei, Volltext: https://medicaljournalssweden.se/actadv/article/view/44135 
|
| Verfasserangaben: | Amelie Kraaz, Wiebke K. Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt and Juliane Weilandt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1942693710 | ||
| 003 | DE-627 | ||
| 005 | 20251201160135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251127s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2340/actadv.v105.44135 |2 doi | |
| 035 | |a (DE-627)1942693710 | ||
| 035 | |a (DE-599)KXP1942693710 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kraaz, Amelie |e VerfasserIn |0 (DE-588)1382826583 |0 (DE-627)1942694075 |4 aut | |
| 245 | 1 | 0 | |a Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma |b a nationwide discrete choice experiment |c Amelie Kraaz, Wiebke K. Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt and Juliane Weilandt |
| 264 | 1 | |c Sep 25, 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.11.2025 | ||
| 520 | |a Adjuvant treatment decisions in stage IIB/C melanoma require careful weighing of benefits and risks. Our aim was to investigate how dermato-oncologists in Germany prioritize efficacy, toxicity, and application mode of modern adjuvants in these stages. In a nationwide discrete choice experiment physicians evaluated hypothetical treatment scenarios that varied in recurrence risk, risk of severe adverse events, type of adverse events, and mode of administration. Two patient profiles were presented, including a 55-year-old healthy patient in stage IIB (P1) and an 83-year-old patient in stage IIC with comorbidity (P2). Physicians (n = 112) preferred adjuvant therapy to the opt-out option in 86.4% of scenarios for P1 and in 60.5% for P2. The risk of severe adverse events was considered most important for both patients and significantly more relevant for P2 (relative importance score (RIS) 53.6 vs 40.2, p < 0.001), while recurrence risk was more relevant for P1 (RIS 36.3 vs 21.8, p < 0.001). Immune-related adverse events were less acceptable than gastrointestinal symptoms or pyrexia. Infusions at longer intervals were favoured compared with oral therapies. In conclusion, dermato-oncologists prioritized safety over efficacy, particularly in the older, comorbid patient. These preferences should be reconciled with patients’ preferences and treatment goals during shared decision-making. | ||
| 650 | 4 | |a conjoint analysis | |
| 650 | 4 | |a immune checkpoint inhibitors | |
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a treatment preferences | |
| 700 | 1 | |a Peitsch, Wiebke K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ratusznik, Laura |e VerfasserIn |4 aut | |
| 700 | 1 | |a Diehl, Katharina |d 1984- |e VerfasserIn |0 (DE-588)1028339259 |0 (DE-627)730593738 |0 (DE-576)375833587 |4 aut | |
| 700 | 1 | |a Kromer, Christian |d 1990- |e VerfasserIn |0 (DE-588)1075522846 |0 (DE-627)83338886X |0 (DE-576)44362500X |4 aut | |
| 700 | 1 | |a Akbarzadeh, Dilan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schaarschmidt, Marthe-Lisa |d 1986- |e VerfasserIn |0 (DE-588)1033397377 |0 (DE-627)741158892 |0 (DE-576)380994593 |4 aut | |
| 700 | 1 | |a Weilandt, Juliane |e VerfasserIn |0 (DE-588)1213487935 |0 (DE-627)1724137263 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta dermato-venereologica |d Uppsala : Acta Dermato-Venereologica, 1921 |g 105(2025), Artikel-ID adv44135, Seite 1-8 |h Online-Ressource |w (DE-627)302725431 |w (DE-600)1492617-9 |w (DE-576)081952848 |x 1651-2057 |7 nnas |a Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma a nationwide discrete choice experiment |
| 773 | 1 | 8 | |g volume:105 |g year:2025 |g elocationid:adv44135 |g pages:1-8 |g extent:8 |a Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma a nationwide discrete choice experiment |
| 856 | 4 | 0 | |u https://doi.org/10.2340/actadv.v105.44135 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://medicaljournalssweden.se/actadv/article/view/44135 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251127 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1033397377 |a Schaarschmidt, Marthe-Lisa |m 1033397377:Schaarschmidt, Marthe-Lisa |d 60000 |d 61900 |e 60000PS1033397377 |e 61900PS1033397377 |k 0/60000/ |k 1/60000/61900/ |p 7 | ||
| 999 | |a KXP-PPN1942693710 |e 4814777760 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 27.11.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1942693710","language":["eng"],"person":[{"given":"Amelie","family":"Kraaz","role":"aut","display":"Kraaz, Amelie","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Peitsch, Wiebke K.","role":"aut","family":"Peitsch","given":"Wiebke K."},{"roleDisplay":"VerfasserIn","display":"Ratusznik, Laura","role":"aut","family":"Ratusznik","given":"Laura"},{"family":"Diehl","given":"Katharina","display":"Diehl, Katharina","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kromer, Christian","given":"Christian","family":"Kromer"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Akbarzadeh, Dilan","given":"Dilan","family":"Akbarzadeh"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Schaarschmidt, Marthe-Lisa","given":"Marthe-Lisa","family":"Schaarschmidt"},{"display":"Weilandt, Juliane","roleDisplay":"VerfasserIn","role":"aut","family":"Weilandt","given":"Juliane"}],"title":[{"subtitle":"a nationwide discrete choice experiment","title":"Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma","title_sort":"Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma"}],"physDesc":[{"noteIll":"Diagramme","extent":"8 S."}],"relHost":[{"recId":"302725431","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Preferences of dermato-oncologists for adjuvant therapy in stage II melanoma a nationwide discrete choice experimentActa dermato-venereologica","note":["Fortsetzung der Druck-Ausgabe","Volltext auch als Teil einer Datenbank verfügbar","Gesehen am 16.10.24"],"titleAlt":[{"title":"ActaDV"}],"part":{"extent":"8","volume":"105","text":"105(2025), Artikel-ID adv44135, Seite 1-8","pages":"1-8","year":"2025"},"pubHistory":["Volume 2, issue 2 (1921) [?]-"],"title":[{"subtitle":"a journal for clinical and experimental research in the field of dermatology and venereology","title":"Acta dermato-venereologica","title_sort":"Acta dermato-venereologica"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1651-2057"],"zdb":["1492617-9"],"eki":["302725431"]},"origin":[{"publisherPlace":"Uppsala ; Uppsala ; London [u.a.]","dateIssuedDisp":"[1921?]-","publisher":"Acta Dermato-Venereologica ; Medical Journals Sweden AB ; Taylor & Francis"}]}],"name":{"displayForm":["Amelie Kraaz, Wiebke K. Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt and Juliane Weilandt"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"Sep 25, 2025"}],"id":{"eki":["1942693710"],"doi":["10.2340/actadv.v105.44135"]}} | ||
| SRT | |a KRAAZAMELIPREFERENCE2520 | ||